

OPTIMA HEALTH PLAN

PHARMACY PRIOR AUTHORIZATION REQUEST FORM*

Directions: *The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request. All other information may be filled in by office staff and faxed to 757-552-7516 or 1-800-750-9692. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct.*

Drug Name: 17-hydroxyprogesterone Caproate (17-OHPC)

- 17-Hydroxyprogesterone caproate (17-OHPC) is a synthetic (artificial) hormone injection based on 17-Hydroxyprogesterone, which is a natural progestin and in pregnancy increases in the third trimester primarily due to fetal adrenal production.
- This hormone is primarily produced in the adrenal glands and to some degree in the gonads, specifically the corpus luteum of the ovary. Normal levels are 3-90 ng/dl in children and in women, 15-70 ng/dl prior to ovulation, and 35-290 ng/dl during the luteal phase.
- Studies show that 17-OHPC is helpful for the prevention of pre-term birth in pregnant women with a history of at least one spontaneous preterm birth
- Pre-term birth is defined as a birth prior to 37 weeks gestational age.
- Findings from a multicenter, randomized, placebo-controlled, double-blind clinical trial of 17OHP-C in women at high risk for pre-term birth sponsored by the National Institute for Child Health and Human Development (NICHD) showed a 34% reduction in pre-term births prior to 37 weeks in women with a prior pre-term birth (a population at high risk for a recurrent pre-term birth)

Please complete below: (All lines must be checked to qualify)

- Patient has a history of previous spontaneous birth at less than 37 weeks gestation and current pregnancy is a singleton pregnancy
- Length of therapy needed _____

Patient: _____

Member Number: _____

SIGNED _____ **DATE** _____

Physician Name _____ **Phone Number** _____

Fax Number _____

Pharmacy Name _____ **Pharmacy Tel #** _____

(IF AVAILABLE)